DIVA logo

Funding: NHLBI
Investigator: Foglia, E

The DIVA Trial is a National Heart, Lung and Blood Institute funded multicenter randomized comparative effectiveness trial comparing 2 FDA-approved modes of respiratory support to prevent extubation failure among extremely preterm infants. The preterm (23-28 weeks gestation) babies will be randomly placed into either a non-invasive neurally adjusted ventilatory assist or non-synchronized nasal intermittent positive pressure ventilation treatment for bronchopulmonary dysplasia.  Bronchopulmonary dysplasia is the most common complication for premature babies and is the leading respiratory cause of death.

Logo for EMO

Funding: NHLBI
Investigator(s): Bonafide, C

The EMO effectiveness deimplementation trial, funded by the National Heart, Lung, and Blood Institute is a four-phase project seeking to eliminate monitor over use in children with bronchiolitis and to identify a de-implementation strategy.  Bronchiolitis is the leading cause of infant hospitalization.  There are over 100,000 admissions and 1.7 billion dollars in hospital charges.  Pulse oximetry is a common intervention but does not improve outcomes for patients during hospitalization when supplemental oxygen is being administered.  This study discourages the continuous use of monitoring SPO2 for children who are in room air which will maximize quality and minimize waste in our health care. 

logo for SACRED

Funding: VA Office of Research and Development
Investigators: Kaplan, DE; Taddei, TH

The SACRED Study is a prospective phase 3, double-blind, randomized, placebo-controlled, multi-center study. The study is being conducted at 10 VA centers across the country. The primary objective is to test the effectiveness of simvastatin in reducing the incidence of hepatic decompensation, hepatocellular carcinoma, or all cause mortality in patients with cirrhosis at high risk. Secondary objectives include looking to explore the interaction of SLCO1B1 and KIF6 polymorphism on safety and clinical efficiency of statin therapy in patients with compensated cirrhosis, and to assess the impact of statin exposure on health related quality of life.

image

Dr. Kristin Linn was awarded a methodological supplement to an ongoing R01 led by Dr. Rinad Beidas at Northwestern University.

Christina H.W. Brotman, MD MSCE

Christina Hao Wang Brotman, MD, MSCE

Dr. Brotman is a clinical nephrologist and epidemiologist whose research focuses on advanced hemodynamic monitoring and dialysis techniques for acute kidney injury and chronic kidney disease. She has a broad background in biomedical engineering and epidemiology, with specific training in hierarchical modeling of longitudinal data and incorporation of advanced technology into clinical application. She has worked on various translational projects, including mathematical models for tumor growth, functional imaging, alternative serum biomarkers to guide clinical diagnostic and treatment decisions, and use of machine learning algorithms to assess the risk of acute kidney injury. She developed a novel method to quantify a semi-instantaneous rate of vascular refilling that could be monitored continuously throughout hemodialysis and studied its association with circulatory instability during hemodialysis treatments. This work has laid the foundation for a line of inquiry in the use of advanced monitoring techniques to improve the precision and tolerance of fluid removal during hemodialysis. She is currently studying the acute impacts of hemodialysis on various areas of systemic and local perfusion, including changes in blood pressure, plasma refill, and cardiac and cerebral perfusion and function. Her work has been funded by the National Institute of Health (NIH) and Industry-sponsored grants. She also teaches various topics related to nephrology and epidemiology to medical students, residents, and fellows, and she serves as a research mentor to medicine residents and fellows in the Perelman School of Medicine’s nephrology division. 

Sunday, September 8, 2024 - Wednesday, September 11, 2024
12:00 am - 11:59 pm
Subscribe to